Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Says 30,000-40,000 Patients Are On Standby For Cypher Approval

This article was originally published in The Gray Sheet

Executive Summary

Interventional cardiologists are delaying a significant number of conventional stenting procedures as they anticipate near-term FDA approval of Johnson & Johnson's sirolimus-eluting Cypher stent

You may also be interested in...



J&J Forecasts Quicker EU Conversion To Cypher In Wake Of FDA Sign-Off

U.S. approval of Johnson & Johnson/Cordis' Cypher sirolimus-eluting stent will exert pressure on key European markets to pay for the device despite its significant price premium over conventional coronary stents, the company asserts

Novartis Logs Into India With Digital Innovation Hub

Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.

UsernamePublicRestriction

Register

MT018241

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel